We are glad to announce that Dr. Dragan Grabulovski has joined us as our business coach and will help us with identifying our best business opportunities and to reach our strategic objectives.
Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.
“I am impressed by the technology developed at Technische Universität Dresden that improves the cell microenvironment of standard cell culture assays, enabling researchers to perform cell assays that were challenging or impossible in the past and yielding better and reproducible results in general,” said Dr. Dragan Grabulovski.
We had supportive and intense discussion during a fruitful meeting in Dresden last week, and we are very much looking forward to our future collaboration!
